Lenvatinib is a medication used to treat various types of cancer, including thyroid cancer and kidney cancer. It is a multikinase inhibitor that works by blocking the signals that promote tumor growth and angiogenesis (the formation of new blood vessels that supply nutrients to tumors). Lenvatinib is also known by various synonyms such as Kisplyx and E7080. In this article, we will discuss the chemical properties, health benefits, potential effects, product mechanism, safety, side effects, dosing information, and conclusion of Lenvatinib.
Chemical name:
The IUPAC name of Lenvatinib is 4-(3-chloro-4-cyclopropylaminopyrrolo[2,1-f][1,2,4]triazin-6-yloxy)-N-methylpyridine-2-carboxamide.
Molecular formula:
The molecular formula of Lenvatinib is C21H19ClN4O4.
Formula weight:
The formula weight of Lenvatinib is 426.86 g/mol.
CAS No:
The CAS number of Lenvatinib is 417716-92-8.
Top ten keywords from Google and Synonyms:
Health benefits of this product:
Lenvatinib is primarily used for the treatment of various types of cancer, including thyroid cancer and kidney cancer. By inhibiting the signals that promote tumor growth and angiogenesis, Lenvatinib can slow or stop the progression of cancer and improve outcomes in patients with advanced or metastatic disease.
Potential effects:
Lenvatinib may have potential effects on the body and mind if not used properly. It can cause hypertension, proteinuria, and electrolyte imbalances, especially in patients with pre-existing cardiovascular or renal conditions. It can also interact with other medications and supplements, so it is important to disclose all medications and substances being used to healthcare providers.
Product mechanism:
Lenvatinib works by inhibiting multiple tyrosine kinases, which are involved in tumor growth and angiogenesis. The drug targets several pathways simultaneously, including vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF), to block the formation of new blood vessels and reduce nutrient supply to tumors.
Safety:
Lenvatinib is generally considered safe when used as directed. However, caution should be exercised when taking the medication with other blood pressure medications or diuretics, as these combinations can increase the risk of hypertension and electrolyte imbalances. It can also cause fetal harm and should not be used during pregnancy.
Side effects:
The side effects of Lenvatinib include hypertension, fatigue, diarrhea, nausea, decreased appetite, and weight loss. In rare cases, it may cause more severe side effects such as arterial thromboembolic events, proteinuria, or liver damage. Patients with pre-existing cardiovascular or renal conditions should consult their healthcare provider before using Lenvatinib.
Dosing information:
The dosing of Lenvatinib varies depending on the indication and individual patient needs. When used for thyroid cancer, the starting dose is typically 24 mg once daily, with adjustments made based on individual response. When used for kidney cancer, the recommended dose is 18 mg once daily.
Conclusion:
In summary, Lenvatinib is a multikinase inhibitor medication used primarily for the treatment of various types of cancer, including thyroid cancer and kidney cancer. The compound works by inhibiting multiple tyrosine kinases, which are involved in tumor growth and angiogenesis. While it can be effective in managing cancer and improving outcomes, caution must be exercised when using the medication due to its potential for interactions and rare but serious side effects. It is important to follow proper dosing and safety protocols when using Lenvatinib to prevent adverse health effects and optimize its therapeutic benefits
